The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update, Special dividend & Acquisition

21 Jul 2016 07:00

RNS Number : 7820E
Tristel PLC
21 July 2016
 

 

 

Tristel plc

("Tristel", the "Group" or the "Company")

 

Trading update and special dividend

Acquisition of the business and assets of its Australian distributor

& Notice of results

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products provides a trading update for the year ended 30 June 2016, declares a special dividend and announces the acquisition of the business and assets of its Australian distributor.

 

Trading update and special dividend

 

For the year ended 30 June 2016 Tristel will record turnover in excess of £17 million (2015: £15.3 million) and pre-tax profit (before share-based payments and unrealised currency gains) of at least £3.1 million (2015: £2.6 million). Both turnover and pre-tax profit are ahead of market expectations.

 

In the second half, revenue from overseas markets contributed 41% of the Group total compared to 36% in the first half, and for the full year overseas revenue represented 39% of Group revenue - a record level.

 

Tristel has continued to generate significant levels of cash and at 30 June 2016 cash balances were £5.7 million compared to £4.0 million at 30 June 2015. The Company has no debt.

 

Accordingly the Board has decided to return to shareholders the portion of this cash that it considers surplus to its investment and operational requirements and announces a special dividend of three pence per share payable on 5 August 2016 to shareholders on the register on 29 July 2016. The corresponding ex-dividend date is 28 July 2016. The Company expects to declare a final dividend for the year at the time of the preliminary results to be announced in October. The level of the final dividend will be determined in accordance with the Company's prevailing normal dividend policy: earnings per share to cover the dividend by at least two times.

 

After the payment of this special dividend and payment of the consideration associated with the acquisition referred to below, the Company's ongoing intention is to retain cash reserves in excess of £3.0 million. The Company last paid a special dividend of 3 pence per share in August 2015.

 

Acquisition of Australian distributor's business

 

Tristel has acquired the assets and business of Ashmed Pty Ltd, Melbourne. Since 2011 Ashmed has acted as the Company's distributor in Australia for the Tristel Wipes System. The consideration is AU$1.35 million plus certain compensation payments for the re-purchase of inventory. The management team is staying with the business.

 

The distributorship achieved sales of approximately AU$3 million during the year ended 30 June 2016 and is profitable. Tristel expects the acquisition to improve significantly its margins on sales to the Australian hospital market and the acquisition will be earnings enhancing. The Company expects the business to contribute incremental earnings of at least £100,000 during the current financial year.

 

Trading outlook

 

Tristel continues to make solid progress both in the United Kingdom and overseas. The Company's plans to enter the United States market remain on track following a successful meeting with the Food and Drug Administration (FDA) in Washington on 28 April 2016. The Company also continues to actively pursue registrations with the Environmental Protection Agency (EPA). Following the FDA meeting and detailed investigation into the product approval requirements of the EPA, Tristel has multiple test programmes underway. The Board expects to be in a position to provide a detailed assessment of progress at the time of the preliminary results.

 

Shareholder Open Day

 

Tristel is today hosting an Open Day for Shareholders at the Company headquarters in Snailwell, Cambridgeshire. A presentation will be made during the Open Day; however, no new material information will be disclosed during the course of the day. The presentation will be available shortly on the Company website: www.tristel.com/investor-centre

 

Notice of results

 

The Company expects to announce its preliminary results for the year ended 30 June 2016 on 17 October 2016.

 

Francisco Soler, Chairman of Tristel plc, comments:

"The Company enjoyed very strong second half growth in both the UK and overseas compared to last year. UK revenues in the second half were £5.3 million, an increase of 10.4% on last year's £4.8 million. An excellent performance overseas resulted in second half revenue of £3.7 million compared to £3.1 million last year, an increase of 19.4%.The proportion of our revenues that are generated overseas continues to increase, and we intend to maintain this trend. I look forward to the Group continuing its expansion in the years ahead and to providing further detail with regards to the United States regulatory project in October."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

 

Liz Dixon, Finance Director

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

finnCap

Tel: 020 7220 0500

Geoff Nash/ Giles Rolls (Corporate Finance)

 

Alice Lane (Corporate Broking)

 

   

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGMGZNKGNGVZM
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.